Award
NIH Reporter #11179154
Inhibiting beta-adrenergic and COX-2 signaling during the perioperative period to reduce ovarian cancer progression
Recipient
TEL AVIV UNIVERSITY
Award Amount
$137,569.00
Ceiling
$137,569.00
Awarded
August 28, 2025
Identifier
11179154
A clinical trial funded by the National Cancer Institute to test repurposed medications for reducing ovarian cancer progression, focusing on safety and molecular tumor characteristics.
Description
The project involves a clinical trial to test the efficacy of repurposed medications (propranolol and etodolac) in reducing ovarian cancer progression. The project aims to conduct a small exploratory randomized controlled trial with primary outcomes including safety, tolerability, adherence, and molecular characteristics of tumors. The intervention is based on inexpensive, off-patent medications that can be implemented widely.